Gilead Sciences and PANTHERx Partner for LIVDELZI distribution

Gilead Sciences has collaborated with PANTHERx Rare to provide LIVDELZI, a medication aimed at adults suffering from primary biliary cholangitis (PBC). The goal of the partnership is to offer patients the specific peroxisome proliferator-activated receptor delta (PPARδ) agonist.

The FDA recently approved accelerated authorization for LIVDELZI (seladelpar) to treat PBC in adult patients. Approval depends on the treatment showing decreased levels of alkaline phosphatase.

LIVDELZI is designed to be combined with ursodeoxycholic acid (UDCA) for patients with PBC who do not respond well to UDCA, or as a standalone treatment for those who cannot handle it. Mostly middle-aged women are mainly affected by primary biliary cholangitis, a rare and chronic liver condition, but it can also be seen in men.

The illness is defined by harm to the liver's tiny bile ducts, resulting in cholestasis and the buildup of harmful bile acids. Symptoms like exhaustion and severe itching can greatly impact the quality of life for patients. If left untreated, PBC can result in permanent liver harm and possibly result in liver failure.

PANTHERx Rare focuses on delivering orphan drugs and offering vital support services. The goal of the company is to enhance the quality of life for individuals with uncommon and severe illnesses by providing them with cutting-edge medications and top-notch clinical care. Rob Snyder, executive chair of PANTHERx Rare Pharmacy, stated that individuals with rare and severe diseases should have the opportunity to receive treatment that is effective for their specific needs.

“The partnership with Gilead Sciences aims to positively impact key clinical outcomes for those suffering from Primary Biliary Cholangitis and we are pleased to be a part of that.”